Expression STUDIES

Expression studies with normal and diseased models may provide better understanding of associated pathways and disease biology. Compound profiling for drug effects on target expression can help to gain insights into drug interactions with targets, therapeutics efficacy and any associated drug toxicity. Expression studies include:

  • Compound effect on target expression levels measuring protein expression, mRNA levels and secreted levels
  • Assay formats: Western blotting, qPCR, ELISA, HTRF and AlphaLisa
  • Transfections (transient/ stable) and transductions
  • Compound profiling
  • Mechanism of action studies (MOA)
  • Target validation
  • siRNA knockdown studies
  • Transcription factor-activation profiling specific to project (e.g., cancer,  neurodegenerative, T-cell activation, insulin resistance, etc.)
  • Sample type: cells, blood and tissues (e.g., from xenograft studies)
  • Biomarker levels: e.g. PSA, c-Myc and etc.


Functional assays assist in understanding the ability of drugs to regulate signalling pathways and intracellular messengers. Regulation of a specific signalling pathway may have therapeutic merit and functional assays could help improve the therapeutic efficacy of a drug and reduce adverse effects. Functional assays include: 

GPCR assays: Constitutive activity check, transient and stable transfections, generation of stable clones, assay development and screening.

  • Compound profiling for potency, target and species selectivity
  • Assay formats: cAMP, IP-1, β-Arrestin, Ca flux, reporter assays and downstream phosphorylation levels

Project specific endpoint response measurement: 

  • Oncology, immunology and inflammation pathway specific end-point measurement (e.g. Cytokines, pSTATs, biomarker levels, bioassays, chemotaxis, phagocytosis and etc)
  • Compound profiling and Mechanism of action studies (MOA)